Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
Public ClinicalTrials.gov record NCT00406315. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.
Study identification
- NCT ID
- NCT00406315
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 255 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2006 (Type not available)
- Primary completion
- Dec 2008 (Actual)
- Completion
- Mar 2009 (Actual)
- Last update posted
- Mar 29, 2021
2006 – 2009
United States locations
- U.S. sites
- 28
- U.S. states
- 13
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85028 | — |
| Pfizer Investigational Site | Costa Mesa | California | 92626 | — |
| Pfizer Investigational Site | Garden Grove | California | 92845 | — |
| Pfizer Investigational Site | National City | California | 91950 | — |
| Pfizer Investigational Site | Orange | California | 92868-8040 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | Temecula | California | 92591 | — |
| Pfizer Investigational Site | Torrance | California | 90505 | — |
| Pfizer Investigational Site | Hialeah | Florida | 33016 | — |
| Pfizer Investigational Site | Miami | Florida | 33126 | — |
| Pfizer Investigational Site | Miami | Florida | 33143 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60640 | — |
| Pfizer Investigational Site | Des Plaines | Illinois | 60016 | — |
| Pfizer Investigational Site | Oakbrook Terrace | Illinois | 60181 | — |
| Pfizer Investigational Site | Schaumburg | Illinois | 60194 | — |
| Pfizer Investigational Site | Topeka | Kansas | 66606 | — |
| Pfizer Investigational Site | Olive Branch | Mississippi | 38654 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63368 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89102 | — |
| Pfizer Investigational Site | Nashua | New Hampshire | 03060 | — |
| Pfizer Investigational Site | Olean | New York | 14760 | — |
| Pfizer Investigational Site | Staten Island | New York | 10312 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38117 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38133 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | DeSoto | Texas | 75115 | — |
| Pfizer Investigational Site | Bothell | Washington | 98011 | — |
| Pfizer Investigational Site | Kirkland | Washington | 98033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00406315, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2021 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00406315 live on ClinicalTrials.gov.